Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$21.88 USD
-0.34 (-1.53%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $21.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
ELVN 21.88 -0.34(-1.53%)
Will ELVN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELVN
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Ex-congressional candidate and FTX executive's romantic partner indicted on campaign finance charges
Enliven price target raised by $5 at Mizuho, here's why
Enliven Therapeutics GAAP EPS of -$0.41
Buy Rating for Enliven Therapeutics Backed by Promising Clinical Data and Market Potential
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update